What one share of Evommune holds
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”).
Evommune’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.44 |
|---|---|
| Profit | −$4.18 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.29 |
| Cash and investments | $1.65 |
| Book value | $7.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | $4.64 | −$45.29 | $0.06 | −$38.64 | — | −$92.97 |
| 2025 | $2.12 | −$11.22 | $0.04 | −$12.49 | — | $6.52 |
Common questions about Evommune
How much does one share of Evommune earn?
Over the last 12 months, Evommune lost $4.18 for each share on $0.44 of sales.
Does Evommune pay a dividend?
Evommune didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Evommune’s book value per share?
Evommune’s book value is $7.65 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Evommune have?
Each share of Evommune has $1.65 of cash and investments, as of June 30, 2026.
What is Evommune’s free cash flow per share?
−$3.29 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.